{"id":"NCT05076149","sponsor":"Vertex Pharmaceuticals Incorporated","briefTitle":"A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation","officialTitle":"A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive CFTR Mutation and No F508del Mutation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-10-27","primaryCompletion":"2023-05-18","completion":"2023-11-30","firstPosted":"2021-10-13","resultsPosted":"2024-06-13","lastUpdate":"2024-06-13"},"enrollment":597,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Cystic Fibrosis"],"interventions":[{"type":"DRUG","name":"VX-121/TEZ/D-IVA","otherNames":["VX-121/VX-661/CTP-656","VX-121/VX-661/VX-561","VX-121/tezacaftor/deutivacaftor"]},{"type":"DRUG","name":"ELX/TEZ/IVA","otherNames":["VX-445/VX-661/VX-770","elexacaftor/tezacaftor/ivacaftor"]},{"type":"DRUG","name":"IVA","otherNames":["VX-770","ivacaftor"]},{"type":"DRUG","name":"Placebo (matched to VX-121/TEZ/D-IVA)","otherNames":[]},{"type":"DRUG","name":"Placebo (matched to ELX/TEZ/IVA)","otherNames":[]},{"type":"DRUG","name":"Placebo (matched to IVA)","otherNames":[]}],"arms":[{"label":"ELX/TEZ/IVA","type":"ACTIVE_COMPARATOR"},{"label":"VX-121/TEZ/D-IVA","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants who are homozygous for F508del, heterozygous for F508del and a gating (F/G) or residual function (F/RF) mutation, or have at least 1 other TCR CF transmembrane conductance regulator (CFTR) gene mutation and no F508del mutation.","primaryOutcome":{"measure":"Absolute Change in Percent Predicted Forced Expiratory Volume in 1second (ppFEV1)","timeFrame":"From Baseline Through Week 24","effectByArm":[{"arm":"ELX/TEZ/IVA","deltaMin":0,"sd":null},{"arm":"VX-121/TEZ/D-IVA","deltaMin":0.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.0001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":170,"countries":["United States","Australia","Austria","Belgium","Canada","Denmark","France","Germany","Greece","Hungary","Ireland","Israel","Italy","Netherlands","New Zealand","Norway","Poland","Sweden","Switzerland","United Kingdom"]},"refs":{"pmids":["39756424","37983082"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":40,"n":289},"commonTop":["Infective pulmonary exacerbation of cystic fibrosis","COVID-19","Cough","Nasopharyngitis","Upper respiratory tract infection"]}}